» Articles » PMID: 29042587

MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2

Overview
Journal Sci Rep
Specialty Science
Date 2017 Oct 19
PMID 29042587
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma patients with lung metastasis and local invasion remain challenging to treat despite the significant contribution of the combination of surgery and neo-adjuvant chemotherapy. Our previous microarray study demonstrated that miR-302b had significantly lower expression in osteosarcoma cell lines than in osteoblast cell lines. In the present study, we further elucidated the role of miR-302b in regulating the migration and invasiveness of osteosarcoma. MiR-302b expression was markedly down-regulated in osteosarcoma cell lines and clinical tumour tissues. Lower levels of miR-302b expression were significantly associated with metastasis and high pathological grades. A functional study demonstrated that over-expression of miR-302b suppressed tumour cell proliferation, invasion and migration in vitro and in vivo. Runx2 was identified as a direct target gene for miR-302b by bioinformatics analysis and dual-luciferase reporter gene assay. Moreover, over-expression of miR-302b induced down-regulation of Runx2, OPN, MMP-2, MMP-9, MMP-12, MMP-14, and VEGF in 143B cells. Exogenous expression of Runx2 partially rescued the inhibitory effect of miR-302b on the invasion and migration activity of 143B osteosarcoma cells. Taken together, our results indicate that miR-302b functions as a tumour repressor in the invasion and migration of osteosarcoma by directly downregulating Runx2 expression and may be a potential therapeutic target for osteosarcoma.

Citing Articles

is a potential therapeutic target for osteosarcoma: and evaluations using generated artificial osteosarcoma cancer stem cell‑like cells.

Miyamoto T, Fukase N, Kawamoto T, Fujiwara S, Hara H, Sawada R Oncol Rep. 2024; 53(2).

PMID: 39704263 PMC: 11667212. DOI: 10.3892/or.2024.8857.


Canine soft tissue sarcomas: the expression of RUNX2 and karyopherin alpha-2 in extraskeletal (soft tissues) and skeletal osteosarcomas.

Leonardi L, Manuali E, Bufalari A, Porcellato I Front Vet Sci. 2024; 11:1292852.

PMID: 38362297 PMC: 10867244. DOI: 10.3389/fvets.2024.1292852.


Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.

Todosenko N, Khlusov I, Yurova K, Khaziakhmatova O, Litvinova L Int J Mol Sci. 2023; 24(10).

PMID: 37240338 PMC: 10219319. DOI: 10.3390/ijms24108993.


Research progress on microRNA in gout.

Xie J, He C, Su Y, Ding Y, Zhu X, Xu Y Front Pharmacol. 2022; 13:981799.

PMID: 36339582 PMC: 9631428. DOI: 10.3389/fphar.2022.981799.


Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma.

Cheng S, Wang W J Bone Miner Metab. 2022; 40(4):554-560.

PMID: 35639175 DOI: 10.1007/s00774-022-01319-5.


References
1.
Zhu R, Yang Y, Tian Y, Bai J, Zhang X, Li X . Ascl2 knockdown results in tumor growth arrest by miRNA-302b-related inhibition of colon cancer progenitor cells. PLoS One. 2012; 7(2):e32170. PMC: 3285660. DOI: 10.1371/journal.pone.0032170. View

2.
Zhao Y, Tu M, Wang W, Qiu J, Yu A, Yu A . Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep. 2016; 6:26611. PMC: 4877571. DOI: 10.1038/srep26611. View

3.
He Y, Meng C, Shao Z, Wang H, Yang S . MiR-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem. 2014; 34(5):1485-96. DOI: 10.1159/000366353. View

4.
Khodayari N, Mohammed K, Lee H, Kaye F, Nasreen N . MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells. Am J Cancer Res. 2016; 6(9):1996-2009. PMC: 5043109. View

5.
Rothermundt C, Seddon B, Dileo P, Strauss S, Coleman J, Briggs T . Follow-up practices for high-grade extremity Osteosarcoma. BMC Cancer. 2016; 16:301. PMC: 4859955. DOI: 10.1186/s12885-016-2333-y. View